Y Chen, MA Tortorici, M Garrett, B Hee… - Clinical …, 2013 - Springer
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth
factor receptors 1, 2, and 3 that is approved in the US and several other countries for …